A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors

Part of paid clinical trials in Los Angeles, California.

Sponsor
Bristol-Myers Squibb
Study ID
NCT05888831
Phase
PHASE1/PHASE2
Status
Active Not Recruiting

Conditions

  • Advanced Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • BMS-986449 — DRUG
    Specified dose on specified days
  • Nivolumab — DRUG
    Specified dose on specified days

Study Details

The purpose of this study is to evaluate the safety and efficacy of BMS-986449 alone and in combination with nivolumab in participants with advanced solid tumors.

Key Dates

Start date
Jun 6, 2023
Status verified
Jun 2025
Primary completion
Sep 30, 2026
Completion
Sep 30, 2026

Study Design

Enrollment
100 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Dose Escalation: BMS-986449 monotherapy
  • Experimental: Dose Escalation: BMS-986449 + nivolumab
  • Experimental: Dose Escalation: BMS-986449 monotherapy pharmacodynamic (PD) cohorts

Primary Outcome Measure

Number of participants with Dose-Limiting Toxicities (DLTs) [ Time Frame: Up to approximately 4 years ]

Locations (4)

FacilityCityStateZIPSite coordinators
Local Institution - 0021Los AngelesCalifornia90025-
Local Institution - 0007New HavenConnecticut06510-
Local Institution - 0010HackensackNew Jersey07601-
Local Institution - 0022Lake SuccessNew York11042-

Find similar trials in Los Angeles, CA

By research site
Local Institution - 0021· Los Angeles, CALocal Institution - 0007· New Haven, CTLocal Institution - 0010· Hackensack, NJLocal Institution - 0022· Lake Success, NY

Related Studies